Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
2024年8月8日 - 5:01AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial
results for the second quarter ended June 30, 2024.
“We saw positive growth in the OGM installed base
this quarter, along with key advancements to our VIA software and
the achievement of a significant milestone with the establishment
of a Category I CPT code for OGM, which we believe will raise the
awareness and utility of OGM,” commented Erik Holmlin, PhD,
president and chief executive officer of Bionano. “We are
continuing to focus on strengthening the company’s long-term growth
profile and prioritizing efficiencies as we manage through a
transition into a lower resource environment. We expect to continue
to invest in opportunities where we see the greatest potential to
increase global adoption and utilization of OGM."
Recent Highlights
- Announced a
registered direct offering and concurrent private placement of
clinical milestone-linked Series A and Series B warrants of up to
$30.0 million:
- Upfront
gross proceeds to the Company of
approximately $10.0 million, before
deducting the placement agent’s fees and other offering expenses
payable by the Company; funds will be used for general corporate
purposes.
- Potential
additional gross proceeds of up to $20.0 million upon the cash
exercise (subject to stockholder approval) in full of the Series A
and Series B warrants to purchase an aggregate of
35,026,272 shares.
- Additional
updates and improvements to the Company’s end-to-end workflow are
anticipated for the second half of 2024:
- A pre-commercial
version of the Ionic® Purification System for isolation of DNA for
OGM analysis completed evaluation at two customer sites, with a
third site evaluation underway and a full commercial launch
anticipated for the fourth quarter of 2024. Customers have shared
positive feedback, and validated Ionic’s ability to reduce the OGM
sample-to-answer workflow to as few as two days.
- Improvements to
data analysis processing time on the Stratys™ Compute, a
high-performance workstation developed in collaboration with
NVIDIA, are anticipated for the fourth quarter of 2024. Both
product enhancements are expected to enable more samples to be
processed more efficiently by the same number of technicians in our
customers’ labs.
- Key publications support OGM’s
utility in prenatal and cancer applications:
- A peer-reviewed
publication on the first phase of a multi-site prenatal study,
focused on the concordance and reproducibility of OGM analysis
compared with traditional methodologies, showed that, in a cohort
of 200 samples (123 unique cases), OGM demonstrated an overall
accuracy of 99.6%, sensitivity of 99.5%, specificity of 100%, PPV
of 100%, NPV of 95.5%, and 100% reproducibility between all sites,
operators, and instruments.
- A publication from
The University of Texas MD Anderson Cancer Center that assessed the
utility of OGM in 159 acute myeloid leukemia (AML) cases found that
OGM identified pathogenic variants and provided information on
fusion genes in 48% of cases, leading to potential improvements in
the accuracy of classification and risk stratification.
- The first
multi-site study in multiple myeloma (MM) comparing OGM to
traditional cytogenetic methods for the detection of structural
variants showed that OGM uniquely identified complex genomic
rearrangements that are associated with cancer proliferation and
progression, resulting in a change in prognostication beyond that
indicated by traditional cytogenetic analysis in 18% of cases;
additionally, in 11% of cases, OGM’s unique findings provided
precise information that could be used to predict response to
targeted therapies.
- Full year 2024 revenue
guidance of $36.0 to $40.0 million;
revenue for the third quarter of 2024 is expected to be $7.9 to 8.9
million.
Q2 2024 Highlights
- The
editorial panel of the American Medical Association (AMA)
established a new Category I Current Procedural Terminology (CPT®)
code for the use of OGM in cytogenomic genome-wide
analysis to detect structural and copy number variations
related to hematological malignancies. The CPT code is a key
component in obtaining reimbursement for the OGM-Dx™ HemeOne
laboratory developed test (LDT) from third party payors.
- Completely
retired $15.3 million of outstanding convertible notes for
a redemption payment of $17.6 million and a retirement fee of $2.2
million, with proceeds from a private placement of senior secured
convertible debentures due May 2026; the Company received
gross proceeds of $18.0 million in connection with the
private placement. The financing provides the Company significant
financial flexibility by retiring near-term debt maturities and
extending principal redemption payments.
- Announced a
registered direct offering in April 2024, with upfront gross
proceeds to the Company of
approximately $10.0 million, before
deducting the placement agent’s fees and other offering expenses
payable by the Company; funds will be used for general corporate
purposes.
- Entered into a software
marketing agreement with Revvity, Inc. under which Revvity
will market and commercialize Bionano’s VIA™ software as
part of its newborn sequencing research workflow. VIA is expected
to enhance the comprehensive reporting capabilities of Revvity’s
sequencing solution by adding an assessment of copy number variants
to its next generation sequencing workflow and streamlining the
workflow’s interpretation capabilities.
- Installed base of OGM systems
totaled 363 at the end of the second quarter of 2024,
which represents a 29% increase over the 281 installed systems
reported at the end of the second quarter of 2023.
- 6,165 nanochannel array
flowcells sold during the second quarter of 2024, which
represents a decrease of 13% from the 7,062 flowcells sold during
the second quarter of 2023.
- Announced advancements to the
Company’s suite of comprehensive software analysis tools for
cancer; enhancements include a novel aneusomy caller
feature, Phred-like quality scores for detected variants, enhanced
visualization with VIA circos plots, and customizable reporting
options.
- Three peer-reviewed
publications highlighted OGM’s ability to assess genome integrity
in therapeutic cell lines like chimeric antigen
receptor-modified T cells (CAR-T), stem cells, and cell lines used
for translational research in unraveling genetic causes of
Alzheimer’s disease; taken together, the publications illustrated
that OGM can be highly sensitive for genome-wide detection of on
and off target effects that may limit the utility of stem cell
lines and CAR-T cell products.
Q2 2024 Financial Results
- Total revenue for the second
quarter of 2024 was $7.8 million, a decrease of 10%
compared to the second quarter of 2023.
- GAAP gross margin for the
second quarter of 2024 was 33%, compared to 27% from the
second quarter of 2023. Second quarter 2024 non-GAAP gross margin
was 35%, compared to 29% from the second quarter of 2023. Second
quarter 2024 non-GAAP gross margin excludes $128,000 in stock-based
compensation and $7,000 of restructuring expense.
- Second quarter 2024 GAAP
operating expense was $19.6 million, and $18.8
million on a non-GAAP basis, which is a decrease of 53%
and 46%, respectively, from the second quarter of 2023. Non-GAAP
operating expense in the second quarter of 2024 excludes
restructuring costs, stock-based compensation, and other
adjustments as detailed in the reconciliation table accompanying
this press release. Second quarter 2023 GAAP to non-GAAP
reconciliation can be found in the same table in this release.
- Cash, cash
equivalents, available-for-sale securities, and restricted cash
were $30.3 million as of June 30, 2024. As of June 30,
2024, $11.4 million was subject to certain restrictions. As of June
30, 2024, the aggregate principal amount of senior secured
convertible debentures outstanding was $20.0 million.
- Raised $2.1
million in net proceeds in the second quarter of 2024
through our ATM facility.
Gülsen Kama, chief financial officer at Bionano added, “We were
pleased to see significant year-over-year improvements in operating
expense and cash burn this quarter as a result of the cost savings
initiatives enacted in 2023 and March this year. We remain on track
to reduce annualized non-GAAP operating expenses by approximately
$65.0 to $75.0 million by the first quarter of 2025 as part of our
efforts to extend our cash runway.”
Conference Call & Webcast Details
Date: |
Wednesday, August 7th, 2024 |
Time: |
4:30 p.m. ET |
Participant Link: |
Registration- Click Here |
Webcast Link: |
https://edge.media-server.com/mmc/p/jojadok2/ |
|
|
Participants may access a live webcast of the call on the
Investors page of the Bionano website. A replay of the conference
call and webcast will be archived on Bionano’s investor relations
website at https://ir.bionano.com/ for at least 30 days.
About Bionano
Bionano is a provider of genome analysis
solutions that can enable researchers and clinicians to reveal
answers to challenging questions in biology and medicine. The
Company’s mission is to transform the way the world sees the genome
through optical genome mapping (OGM) solutions, diagnostic services
and software. The Company offers OGM solutions for applications
across basic, translational and clinical research. The Company also
offers an industry-leading, platform-agnostic genome analysis
software solution, and nucleic acid extraction and purification
solutions using proprietary isotachophoresis (ITP) technology.
Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the
Company also offers OGM-based diagnostic testing services. For more
information, visit www.bionano.com
and www.bionanolaboratories.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Non-GAAP Financial Measures
To supplement Bionano’s financial results
reported in accordance with U.S. generally accepted accounting
principles (GAAP), the Company has provided non-GAAP gross margin
and non-GAAP operating expense in this press release, which are
non-GAAP financial measures. Non-GAAP operating expense excludes
from GAAP reported operating expense the following components as
detailed in the reconciliation table accompanying this press
release: costs directly attributable to the company restructuring,
stock-based compensation, amortization of intangibles, change in
fair value of contingent consideration and certain deal-related
costs. Non-GAAP gross margin excludes from GAAP reported gross
margin stock-based compensation and certain restructuring expense
as detailed in the reconciliation table accompanying this press
release.
Bionano believes that non-GAAP gross margin and
non-GAAP operating expense are useful to investors and analysts as
a supplement to its financial information prepared in accordance
with GAAP for analyzing operating performance and identifying
operating trends in its business. Bionano uses non-GAAP gross
margin and non-GAAP operating expense internally to facilitate
period-to-period comparisons and analysis of its operating
performance in order to understand, manage and evaluate its
business and to make operating decisions. Accordingly, Bionano
believes these measures allow for greater transparency with respect
to key financial metrics it uses in assessing its own operating
performance and making operating decisions.
These non-GAAP financial measures are not meant
to be considered in isolation or as a substitute for comparable
GAAP measures; should be read in conjunction with the Company’s
consolidated financial statements prepared in accordance with GAAP;
have no standardized meaning prescribed by GAAP; and are not
prepared under any comprehensive set of accounting rules or
principles. In addition, from time to time in the future, there may
be other items that the Company may exclude for purposes of its
non-GAAP financial measures; and the Company may in the future
cease to exclude items that it has historically excluded for
purposes of its non-GAAP financial measures. Likewise, the Company
may determine to modify the nature of its adjustments to arrive at
its non-GAAP financial measures. Because of the non-standardized
definitions of non-GAAP financial measures, the non-GAAP financial
measures as used by Bionano in this press release and the
accompanying reconciliation table have limits in its usefulness to
investors and may be calculated differently from, and therefore may
not be directly comparable to, similarly titled measures used by
other companies.
For a reconciliation of non-GAAP gross margin
and non-GAAP operating expense to gross margin and operating
expense reported in accordance with GAAP, please refer to the
financial tables accompanying this release.
Forward-Looking Statements of Bionano
Genomics
This press release and accompanying conference
call contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“believe,” “estimate,” “expect,” “may,” “plan,” “will” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our revenue guidance; our expectations regarding product uptake,
revenue growth, market development and increased OGM adoption,
including through publications highlighting the utility and
applications of OGM; our growth prospects and future financial and
operating results; the growth of our installed OGM system base; the
sales of our flowcell consumables and the other expectations
related thereto; our commercial expectations, including the
potential to increase global adoption and utilization of OGM; the
anticipated benefits and success of our collaboration efforts;
continued research, presentations and publications involving OGM
and its utility compared to traditional cytogenetics and our
technologies; our ability to drive adoption of OGM and our
technology solutions; any potential proceeds from the exercise of
the Series A and Series B warrants; our plans to hold a special
meeting of stockholders; our cost savings and strategic
productivity initiative including the expected reduction in
annualized operating expenses and the timing for achieving such
reduction; and efforts to extend our cash runway. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the timing and amount of revenue we are able to
recognize in a given fiscal period; the impact of adverse
geopolitical and macroeconomic events, such as recent and potential
future bank failures and the ongoing conflicts between Ukraine and
Russia and in the middle east, on our business and the global
economy; general market conditions, including inflation and supply
chain disruptions; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts and our ability to
continue as a “going concern”; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; study results that differ or contradict the
results mentioned in this press release; our ability to obtain
stockholder approval for the exercise of the Series A and Series B
warrants; and the risks and uncertainties associated with our
business and financial condition in general, including the risks
and uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2023 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:
David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com
BIONANO GENOMICS, INC |
Condensed Consolidated Balance Sheet
(Unaudited) |
|
|
(Unaudited) |
|
|
|
June 30, 2024 |
|
December 31, 2023 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
10,425,000 |
|
|
$ |
17,948,000 |
|
Investments |
|
8,516,000 |
|
|
|
48,823,000 |
|
Accounts receivable, net |
|
6,255,000 |
|
|
|
9,319,000 |
|
Inventory |
|
19,475,000 |
|
|
|
22,892,000 |
|
Prepaid expenses and other current assets |
|
4,889,000 |
|
|
|
6,019,000 |
|
Restricted cash |
|
11,008,000 |
|
|
|
— |
|
Restricted investments |
|
— |
|
|
|
35,117,000 |
|
Total current assets |
|
60,568,000 |
|
|
|
140,118,000 |
|
Restricted cash, net of current portion |
|
400,000 |
|
|
|
400,000 |
|
Property and equipment, net |
|
24,863,000 |
|
|
|
23,345,000 |
|
Operating lease right-of-use asset |
|
4,221,000 |
|
|
|
5,633,000 |
|
Financing lease right-of-use asset |
|
3,402,000 |
|
|
|
3,503,000 |
|
Intangible assets, net |
|
30,021,000 |
|
|
|
33,974,000 |
|
Other long-term assets |
|
5,889,000 |
|
|
|
7,431,000 |
|
Total assets |
$ |
129,364,000 |
|
|
$ |
214,404,000 |
|
|
|
|
|
Liabilities and
stockholders’ equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
8,734,000 |
|
|
$ |
10,384,000 |
|
Accrued expenses |
|
5,530,000 |
|
|
|
8,089,000 |
|
Contract liabilities |
|
1,147,000 |
|
|
|
783,000 |
|
Operating lease liability |
|
2,139,000 |
|
|
|
2,163,000 |
|
Finance lease liability |
|
266,000 |
|
|
|
272,000 |
|
Purchase option liability (at fair value) |
|
— |
|
|
|
8,534,000 |
|
Convertible notes payable (at fair value) |
|
19,359,000 |
|
|
|
69,803,000 |
|
Total current liabilities |
|
37,175,000 |
|
|
|
100,028,000 |
|
Operating lease liability, net of current portion |
|
2,242,000 |
|
|
|
3,590,000 |
|
Finance lease liability, net of current portion |
|
3,564,000 |
|
|
|
3,585,000 |
|
Contingent consideration |
|
5,774,000 |
|
|
|
10,890,000 |
|
Long-term contract liabilities |
|
272,000 |
|
|
|
154,000 |
|
Total liabilities |
|
49,027,000 |
|
|
|
118,247,000 |
|
Stockholders’ equity: |
|
|
|
Common stock |
|
7,000 |
|
|
|
5,000 |
|
Preferred Stock |
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
709,187,000 |
|
|
|
677,337,000 |
|
Accumulated deficit |
|
(628,854,000 |
) |
|
|
(581,208,000 |
) |
Accumulated other comprehensive income (loss) |
|
(3,000 |
) |
|
|
23,000 |
|
Total stockholders’
equity |
|
80,337,000 |
|
|
|
96,157,000 |
|
Total liabilities and
stockholders’ equity |
$ |
129,364,000 |
|
|
$ |
214,404,000 |
|
|
|
|
|
Bionano Genomics, Inc. |
Condensed Consolidated Statement of Operations
(Unaudited) |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenue: |
|
|
|
|
|
|
|
Product revenue |
$ |
6,510,000 |
|
|
$ |
6,609,000 |
|
|
$ |
13,338,000 |
|
|
$ |
12,056,000 |
|
Service and other revenue |
|
1,261,000 |
|
|
|
2,053,000 |
|
|
|
3,202,000 |
|
|
|
4,021,000 |
|
Total revenue |
|
7,771,000 |
|
|
|
8,662,000 |
|
|
|
16,540,000 |
|
|
|
16,077,000 |
|
Cost of revenue: |
|
|
|
|
|
|
|
Cost of product revenue |
|
4,703,000 |
|
|
|
4,752,000 |
|
|
|
9,607,000 |
|
|
|
8,610,000 |
|
Cost of service and other revenue |
|
483,000 |
|
|
|
1,602,000 |
|
|
|
1,525,000 |
|
|
|
3,090,000 |
|
Total cost of revenue |
|
5,186,000 |
|
|
|
6,354,000 |
|
|
|
11,132,000 |
|
|
|
11,700,000 |
|
Operating expenses: |
|
|
|
|
|
|
|
Research and development |
|
6,831,000 |
|
|
|
14,610,000 |
|
|
|
16,608,000 |
|
|
|
28,547,000 |
|
Selling, general and administrative |
|
11,557,000 |
|
|
|
26,936,000 |
|
|
|
31,092,000 |
|
|
|
52,913,000 |
|
Restructuring costs |
|
1,215,000 |
|
|
|
— |
|
|
|
5,847,000 |
|
|
|
— |
|
Total operating expenses |
|
19,603,000 |
|
|
|
41,546,000 |
|
|
|
53,547,000 |
|
|
|
81,460,000 |
|
Loss from operations |
|
(17,018,000 |
) |
|
|
(39,238,000 |
) |
|
|
(48,139,000 |
) |
|
|
(77,083,000 |
) |
Other income (expenses): |
|
|
|
|
|
|
|
Interest income |
|
457,000 |
|
|
|
689,000 |
|
|
|
1,500,000 |
|
|
|
1,392,000 |
|
Other income (expense) |
|
363,000 |
|
|
|
(330,000 |
) |
|
|
(998,000 |
) |
|
|
(288,000 |
) |
Total other income (expense) |
|
820,000 |
|
|
|
359,000 |
|
|
|
502,000 |
|
|
|
1,104,000 |
|
Loss before income taxes |
|
(16,198,000 |
) |
|
|
(38,879,000 |
) |
|
|
(47,637,000 |
) |
|
|
(75,979,000 |
) |
Provision for income
taxes |
|
(26,000 |
) |
|
|
(33,000 |
) |
|
|
(9,000 |
) |
|
|
(59,000 |
) |
Net loss |
$ |
(16,224,000 |
) |
|
$ |
(38,912,000 |
) |
|
$ |
(47,646,000 |
) |
|
$ |
(76,038,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bionano Genomics, Inc. |
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited) |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
GAAP gross margin: |
|
|
|
|
|
|
|
GAAP revenue |
$ |
7,771,000 |
|
|
$ |
8,662,000 |
|
|
$ |
16,540,000 |
|
|
$ |
16,077,000 |
|
GAAP cost of revenue |
|
5,186,000 |
|
|
|
6,354,000 |
|
|
|
11,132,000 |
|
|
|
11,700,000 |
|
GAAP gross profit |
|
2,585,000 |
|
|
|
2,308,000 |
|
|
|
5,408,000 |
|
|
|
4,377,000 |
|
GAAP gross margin % |
|
33 |
% |
|
|
27 |
% |
|
|
33 |
% |
|
|
27 |
% |
|
|
|
|
|
|
|
|
Adjusted non-GAAP gross
margin: |
|
|
|
|
|
|
|
GAAP revenue |
$ |
7,771,000 |
|
|
$ |
8,662,000 |
|
|
$ |
16,540,000 |
|
|
$ |
16,077,000 |
|
GAAP cost of revenue |
|
5,186,000 |
|
|
|
6,354,000 |
|
|
|
11,132,000 |
|
|
|
11,700,000 |
|
Stock-based compensation expense |
|
(128,000 |
) |
|
|
(198,000 |
) |
|
|
(256,000 |
) |
|
|
(344,000 |
) |
COGS restructuring |
|
(7,000 |
) |
|
|
— |
|
|
|
(18,000 |
) |
|
|
— |
|
Adjusted non-GAAP cost of revenue |
|
5,051,000 |
|
|
|
6,156,000 |
|
|
|
10,858,000 |
|
|
|
11,356,000 |
|
Adjusted non-GAAP gross profit |
|
2,720,000 |
|
|
|
2,506,000 |
|
|
|
5,682,000 |
|
|
|
4,721,000 |
|
Adjusted non-GAAP gross margin % |
|
35 |
% |
|
|
29 |
% |
|
|
34 |
% |
|
|
29 |
% |
|
|
|
|
|
|
|
|
GAAP operating expense |
|
|
|
|
|
|
|
GAAP selling, general and administrative expense |
$ |
11,557,000 |
|
|
$ |
26,936,000 |
|
|
$ |
31,092,000 |
|
|
$ |
52,913,000 |
|
Stock-based compensation expense |
|
(2,341,000 |
) |
|
|
(2,433,000 |
) |
|
|
(4,057,000 |
) |
|
|
(4,812,000 |
) |
Intangible asset amortization |
|
(1,714,000 |
) |
|
|
(1,793,000 |
) |
|
|
(3,506,000 |
) |
|
|
(3,585,000 |
) |
Change in fair value of contingent consideration |
|
4,476,000 |
|
|
|
(1,429,000 |
) |
|
|
5,116,000 |
|
|
|
(2,218,000 |
) |
Loss on intangible asset impairment |
|
— |
|
|
|
— |
|
|
$ |
(448,000 |
) |
|
$ |
— |
|
Transaction related expenses |
|
91,000 |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
— |
|
Adjusted non-GAAP selling, general and administrative expense |
|
12,069,000 |
|
|
|
21,281,000 |
|
|
|
28,197,000 |
|
|
|
42,298,000 |
|
GAAP research and development expense |
$ |
6,831,000 |
|
|
$ |
14,610,000 |
|
|
$ |
16,608,000 |
|
|
$ |
28,547,000 |
|
Stock-based compensation expense |
|
(114,000 |
) |
|
|
(1,301,000 |
) |
|
|
(1,285,000 |
) |
|
|
(2,658,000 |
) |
Adjusted non-GAAP research and development expense |
|
6,717,000 |
|
|
|
13,309,000 |
|
|
|
15,323,000 |
|
|
|
25,889,000 |
|
GAAP restructuring costs |
$ |
1,215,000 |
|
|
$ |
— |
|
|
$ |
5,847,000 |
|
|
$ |
— |
|
Restructuring costs |
|
(1,215,000 |
) |
|
|
— |
|
|
$ |
(5,847,000 |
) |
|
$ |
— |
|
Adjusted non-GAAP restructuring costs |
|
— |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
— |
|
Total adjusted non-GAAP
operating expense |
$ |
18,786,000 |
|
|
$ |
34,590,000 |
|
|
$ |
43,520,000 |
|
|
$ |
68,187,000 |
|
|
|
|
|
|
|
|
|
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 7 2024 まで 8 2024
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 8 2023 まで 8 2024